EUVIMEDEUVIMED entdecken
Crossref

Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry

Mychelle Alves Monteiro, Patrícia Condé de Lima, Thiago Santana Novotny, Daniela Silva Santana, Maria Emanuelle Damazio Lima, Anna Sophia Conhasco Lanzellotti Dantas, Laís Oliveira Dos Santos Ferreira, Matheus Nicolau de Souza, Ricardo Luiz do Nascimento Maranho, Soraya de Mendonça Ochs

Journal of Pharmaceutical Sciences · 2023-05 · 112 (5) · 1305-1314

DOI: 10.1016/j.xphs.2023.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023-05. Verfasst von Mychelle Alves Monteiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Quality Control in Health, Oswaldo Cruz Foundation (INCQS/Fiocruz), Rio de Janeiro, RJ, Brazil. Electronic address: mychelle.m…. Hauptthemen laut MEDLINE: Nitrosamines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Agência Nacional de Vigilância Sanitária.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N-nitrosamines (NA) impurities have unexpectedly been found in sartan products, angiotensin II receptor antagonists that are used to control hypertension, representing an urgent concern for industry, global regulators and for the patients. In this study, an HPLC-MS/MS method was developed and validated for the quantification of six NA (N-nitrosodimethylamine, N-Nitroso-N-methyl-4-aminobutyric acid, N-Nitrosodiethylamine, N-ethyl-N-nitroso-2-propanamine, N-nitroso-diisopropylamine and N-nitroso-di-n-butylamine) in losartan, valsartan, olmesartan, irbesartan, candesartan and telmisartan products. The method was validated in terms of sensitivity, linearity, accuracy, precision, robustness and stability. The limits of quantification were 100, 31.25, 250, 33, 312.5 and 125 µg kg-1 in losartan, valsartan, olmesartan, irbesartan, candesartan and telmisartan samples, respectively, which met the sensitivity requirements for the limits set by Food and Drug Administration of the United States. The standard curves showed good linearity. The recoveries ranged from 93.06 to 102.23% in losartan matrix, 83 to 85.9% in valsartan, 96.1 to 101.2% in olmesartan, 89.2 to 97.5% in irbesartan, 93.4 to 132.0% in candesartan and 62.3 to 106.2% in telmisartan matrix. The other parameters met the validation criteria, the good sensitivity and precision, high accuracy and simple and fast analysis provides a reliable method for quality control of NA in sartan pharmaceutical products. The developed method was successfully applied for the determination of N-nitrosamines in 71 sartan products marketed in Brazil.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrosaminesHumansAngiotensin II Type 1 Receptor BlockersChromatography, High Pressure LiquidTandem Mass SpectrometryLosartanCarcinogensIrbesartanPharmaceutical PreparationsTelmisartanBrazilValsartanBenzimidazolesBiphenyl CompoundsTetrazoles

Stichwörter der Autor:innen

Drug contaminationHPLC-MS/MSN-nitrosamine impuritiesNDEANDMASartan products

Substanzen

NitrosaminesAngiotensin II Type 1 Receptor BlockersLosartanCarcinogensIrbesartanPharmaceutical PreparationsTelmisartanValsartancandesartanBenzimidazoles

Autor:innen und Institutionen

  • National Institute for Quality Control in Health, Oswaldo Cruz Foundation (INCQS/Fiocruz), Rio de Janeiro, RJ, Brazil. Electronic address: mychelle.monteiro@incqs.fiocruz.br.
  • National Institute for Quality Control in Health, Oswaldo Cruz Foundation (INCQS/Fiocruz), Rio de Janeiro, RJ, Brazil.
  • National Institute for Quality Control in Health, Oswaldo Cruz Foundation (INCQS/Fiocruz), Rio de Janeiro, RJ, Brazil. Electronic address: soraya.ochs@incqs.fiocruz.br.

Förderung

  • Agência Nacional de Vigilância Sanitária

Zitieren

APA

Monteiro, M. A., de Lima, P. C., Novotny, T. S., Santana, D. S., Lima, M. E. D., Dantas, A. S. C. L., Ferreira, L. O. D. S., de Souza, M. N., Maranho, R. L. D. N., & Ochs, S. M. (2023). Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences, 112(5), 1305-1314. https://doi.org/10.1016/j.xphs.2023.01.005

Vancouver

Monteiro MA, de Lima PC, Novotny TS, Santana DS, Lima MED, Dantas ASCL, et al. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences. 2023;112(5):1305-1314. doi:10.1016/j.xphs.2023.01.005

BibTeX
@article{Monteiro2023,
  author = {Monteiro, Mychelle Alves and de Lima, Patrícia Condé and Novotny, Thiago Santana and Santana, Daniela Silva and Lima, Maria Emanuelle Damazio and Dantas, Anna Sophia Conhasco Lanzellotti and Ferreira, Laís Oliveira Dos Santos and de Souza, Matheus Nicolau and Maranho, Ricardo Luiz do Nascimento and Ochs, Soraya de Mendonça},
  title = {Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2023},
  volume = {112},
  number = {5},
  pages = {1305--1314},
  doi = {10.1016/j.xphs.2023.01.005}
}
Kostenlos starten →